このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

TKA患者におけるNEUROCUPLE™

2026年10月22日 更新者:nCap Medical

革新的な非侵襲性オピオイド節約デバイス (NEUROCUPLE™) による膝関節置換術患者の疼痛管理の強化

This is a randomized (1:1) placebo-controlled clinical trial to determine the feasibility and effectiveness of 30-day application of NEUROCUPLE™ patch for pain reduction and opioid consumption following TKA. Results will establish NEUROCUPLE™ as an effective non-opioid postoperative pain management device for FDA approval. Importantly, we have a placebo device (device without the captor array layer) that looks exactly like the active device, allowing us to conduct a true placebo randomized study.

調査の概要

詳細な説明

Total knee arthroplasty (TKA) is the most common elective surgical procedure. By 2030, 3.5 million TKA procedures are expected1 to be performed. Multiple factors can contribute to an individual's need for TKA; however, the primary factor is osteoarthritis15 and pain. Osteoarthritis affects approximately 32.5 million individuals in the US, leading to an enormous economic burden, ranging from $15-$16 billion dollars annually. Although most diagnosed with osteoarthritis should undergo TKA, the fear of experiencing severe long lasting postoperative pain causes many to postpone the surgery. For those that do elect surgery, postoperative pain decreases quality of life and an increase in risk of chronic opioid use. Out of 98,623 individuals who received TKA from 2015 to 2019, it was reported that 72% received opioid prescriptions in duration and dosage, which was proposed to be the cause of long-term opioid use.

Postoperative pain strategies for TKA often requires opioid use. To mitigate postoperative pain management following TKA a multimodal approach is often used as a part of enhanced recovery after surgery (ERAS) protocols. This approach on the use of on peripheral nerve blocks (PNB)s, acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), and opioids13,18,19. Postoperative opioid and NSAIDS can lead to excessive sedation, vomiting, nausea, hypotension, major bleeding, life-threatening respiratory depression, constipation, renal failure, frequent delayed functional recovery, increase cost of care, and prolong hospital stay. Furthermore, the postoperative prescription of use opioids leads to long-term opioid users in 34.7% to 53.5%. Patients with poorly controlled acute surgical pain are at risk for chronic post-surgical pain, opioid dependence, and long-term opioid use. Thus, there is an urgent and unmet clinical need for a reliable technology to predict and reduce opioid use and costly opioid adverse effects while enhancing surgical pain relief. On an economic point of view, evidence also demonstrates that persistent postoperative pain leads to a loss in work productivity and absenteeism, mounting to an average loss of $13,761 per individual. Therefore, there is a significant need for alternative non-pharmacological, and non-opioid therapies that are effective in treating postoperative pain management in patients undergoing TKA.

Clinical approaches associated with postoperative pain and opioids in TKA. Data compiled from 90 million patients from 38 hospital networks and 18 non-network hospitals demonstrated that reliance on opioids for postoperative pain management is still extremely high (91.5%) following a TKA. Evidence supporting the use of PNBs is lacking and their use may increase the risk of fall. Sharma et al., 2010 reported that femoral nerve blocks conducted in 709 patients lead to postoperative falls (n=13 patients). A study including 250 patients demonstrated that postoperative falls led to an extended hospital stay. Furthermore, nerve injury and major bleeding have also been reported following PNBs. Complementary techniques such as Transcutaneous Electrical Nerve Stimulation (TENS), acupuncture and hypnosis have been proposed but evidence supporting the use of these techniques is still limited and the use of these techniques requires expertise and time. Therefore, current postoperative pain treatments remain unsatisfactory.

A pain relief patch that provides a clinically effective alternative to opioid use for pain management. The scientific premise of our proposal rests upon the published literature and our preliminary data that demonstrates the use of pain relief patches for pain management. Pain and local inflammation following tissue injuries is the result of the release of a number of mediators and ions, decreases in pH (increase in acidity), and changes in local electrical potential. This is in part due to the central nervous system stimulation of nociceptors and the anterior and lateral spinothalamic tracts. The NEUROCUPLE™ device's millions of nanocapacitors capture and release the excess electrical load generated by trauma, thus blocking the transmission of the local pain signals.

An observational study evaluating non-surgical patients' (n=66) using our licensed nanotechnology topical analgesic demonstrated a 71% reduction in Brief Pain Inventory pain severity (Fig. 1), improvements in quality of life, and a 98% reduction in oral pain medication use. Our additional preliminary data in patients undergoing a TKA demonstrated that the use of the patch device plus standard on care was associated with a 36% reduction in pain at rest by postoperative day 3 and more importantly a reduction of 47% in the number of patients requesting an opioid refill beyond their initial prescription within the first 30 days compared to the patients receiving only standard of care. Thus, we believe our clinical data provides a strong scientific premise for utilizing pain relief patches as an alternative to analgesic drugs to provide effective and safe postoperative approach to reduce postoperative analgesia and more importantly to greatly reduce the number of patients requiring long term opioid exposure which has been demonstrated as a risk for postoperative opioid use disorder (OUD) in surgical patients.

研究の種類

介入

入学 (実際)

156

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Pennsylvania
      • Pittsburgh、Pennsylvania、アメリカ、15232
        • UPMC Shadyside Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • >18 years of age
  • Scheduled for elective primary unilateral TKA
  • T-score < 60 on the PROMIS Anxiety measure

Exclusion Criteria:

  • Children (<18 yr.)
  • Pregnant women
  • Active alcoholism (defined as daily use of more than 1 liter of wine and /or 3 or more shots of hard liquor) or drug abuse (defined as daily use of illicit drugs)
  • Severe chronic pain condition that requires daily preoperative opioid dependence
  • T-score ≥ 60 in any of the three PROMIS measures (i.e., sleep, anxiety, and depression)
  • Other concomitant surgery being performed in addition to TKA
  • Patients undergoing bilateral TKA
  • Patients undergoing knee replacement revision
  • Patients with limited mobility (in a wheelchair or requiring a walker)
  • Patients who are not returning home after surgery

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:NEUROCUPLE™ Group

This arm of subjects will receive the active NEUROCUPLE™ patch to wear for 2-weeks following their TKA surgery.

nCAP Medical has developed an effective, safe, non-opioid alternative, the NEUROCUPLE™ device, based on an innovative nanotechnology to reduce surgical pain and facilitate functional recovery while reducing opioid prescriptions, opioid-related adverse events and reducing the cost of care in millions of Americans undergoing TKA each year.

プラセボコンパレーター:Placebo Group

This arm of subjects will receive the placebo (non-active, sham) patch to wear for 2-weeks following their TKA surgery.

The placebo patch is identical to the active patch but with no active agents.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Post-operative Pain at Rest
時間枠:1-Week Post Hospital Discharge

Pain at rest will be assessed by a numerical rate scale (NRS), in which 0 = no pain at all and 10 = the worst pain imaginable

1-Week Post Hospital Discharge

二次結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants With Post-Operative Nausea and Vomiting (PONV) and Antiemetic Use
時間枠:Up to 24-hours post-operatively

Incidence of PONV measured by antiemetic use yes/no

Up to 24-hours post-operatively
Time to Hospital Discharge (Length of Hospital Stay)
時間枠:Up to post-operative day 10

The length of the hospital stay will be abstracted from the medical records, and the mean time and full range will be reported in hours

Up to post-operative day 10
Total Opioid Use in OME (mg) (in Hospital)
時間枠:Up to 24-hours post-operatively

OME measured in mg

Up to 24-hours post-operatively
Total Opioid Use in OME (mg) at 1 Week Post-Hospital Discharge
時間枠:One-week Post Hospital Discharge

OME measured in mg

One-week Post Hospital Discharge
Post-Operative Pain Scores (NRS)
時間枠:Up to 24-hours post-operatively

Assessed by a numerical rate scale (NRS), in which 0 = no pain at all and 10 = the worst pain imaginable

Up to 24-hours post-operatively

その他の成果指標

結果測定
メジャーの説明
時間枠
Baseline Pain at Rest
時間枠:Prior to day of surgery

Pain at rest will be assessed by a numerical rate scale (NRS), in which 0 = no pain at all and 10 = the worst pain imaginable

Prior to day of surgery
Pain While Walking 30 Feet, Baseline
時間枠:Prior to day of surgery

Pain while walking 30 feet will be assessed by a numerical rate scale (NRS), in which 0 = no pain at all and 10 = the worst pain imaginable

Prior to day of surgery
Pain While Walking 30 Feet, 1-week Post-op
時間枠:1-Week Post Hospital Discharge

Pain while walking 30 feet will be assessed by a numerical rate scale (NRS), in which 0 = no pain at all and 10 = the worst pain imaginable

1-Week Post Hospital Discharge
Pain While Walking 30 Feet, 6-weeks Post-op
時間枠:6-Weeks Post Hospital Discharge

Pain while walking 30 feet will be assessed by a numerical rate scale (NRS), in which 0 = no pain at all and 10 = the worst pain imaginable

6-Weeks Post Hospital Discharge
Pain While Walking 100 Feet, Baseline
時間枠:Prior to day of surgery

Pain while walking 100 feet will be assessed by a numerical rate scale (NRS), in which 0 = no pain at all and 10 = the worst pain imaginable

Prior to day of surgery
Pain While Walking 30 Feet, 2-weeks Post-op
時間枠:2-Weeks Post Hospital Discharge

Pain while walking 30 feet will be assessed by a numerical rate scale (NRS), in which 0 = no pain at all and 10 = the worst pain imaginable

2-Weeks Post Hospital Discharge
Pain While Walking 100 Feet, 1-week Post-op
時間枠:1-Week Post Hospital Discharge

Pain while walking 100 feet will be assessed by a numerical rate scale (NRS), in which 0 = no pain at all and 10 = the worst pain imaginable

1-Week Post Hospital Discharge
Pain While Walking 100 Feet, 2-weeks Post-op
時間枠:2-Weeks Post Hospital Discharge

Pain while walking 100 feet will be assessed by a numerical rate scale (NRS), in which 0 = no pain at all and 10 = the worst pain imaginable

2-Weeks Post Hospital Discharge
Pain While Walking 100 Feet, 6-weeks Post-op
時間枠:6-Weeks Post Hospital Discharge

Pain while walking 100 feet will be assessed by a numerical rate scale (NRS), in which 0 = no pain at all and 10 = the worst pain imaginable

6-Weeks Post Hospital Discharge
Opioid Prescriptions Within the First 6-weeks Following Surgery
時間枠:6-Weeks Post Hospital Discharge

The number of opioid refills will be collected via Prescription Drug Monitoring Program (PDMP) for up to 6-weeks following hospital discharge. This will be averaged across each group and reported as a Mean(SD).

6-Weeks Post Hospital Discharge
Patient Satisfaction With Overall Care
時間枠:2-Weeks and 6-Weeks Post Hospital Discharge

Scale from 0 (least satisfied) to 10 (most satisfied)

2-Weeks and 6-Weeks Post Hospital Discharge
Patient Satisfaction With Pain Management
時間枠:2-Weeks and 6-Weeks Post Hospital Discharge

Scale from 0 (least satisfied) to 10 (most satisfied)

2-Weeks and 6-Weeks Post Hospital Discharge
Pain While Walking 100 Feet, 24-hours Post-op
時間枠:24-hours post-operatively

Pain while walking 100 feet will be assessed by a numerical rate scale (NRS), in which 0 = no pain at all and 10 = the worst pain imaginable

24-hours post-operatively
Pain While Walking 30 Feet, 24-hours Post-op
時間枠:24-hours post-operatively

Pain while walking 30 feet will be assessed by a numerical rate scale (NRS), in which 0 = no pain at all and 10 = the worst pain imaginable

24-hours post-operatively

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Jacques E. Chelly, MD, PhD, MBA、University of Pittsburgh / UPMC

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年9月25日

一次修了 (実際)

2025年7月18日

研究の完了 (実際)

2025年7月18日

試験登録日

最初に提出

2024年6月11日

QC基準を満たした最初の提出物

2024年6月11日

最初の投稿 (実際)

2024年6月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月5日

QC基準を満たした最後の更新が送信されました

2026年10月22日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する